Medical Discoveries | Pharma Voice | Experimental | Safety Innovations | Certifications & Approvals | Laboratories
Lilly to seek industry-first FDA nod in autoimmune hair loss after Olumiant’s second trial win
Eli Lilly retakes innovation crown, while Bristol Myers rates most inventive pharma in annual study
Biogen readies Alzheimer’s hopeful aducanumab for U.S. launch as stateside sales plummet
Novo Nordisk, after obesity trial win for injectable semaglutide, plans test for oral version
After cost-cutting spree, Teva chief Schultz nabs big pay bump to nearly $16M
AbbVie’s Rinvoq rollout on track despite JAK safety concerns, but uncertainty remains: analyst
Bristol Myers, flush with pair of CAR-T approvals, blueprints first cell therapy factory in Europe
With demand uncertain and its U.S. manufacturing in limbo, AstraZeneca still aims to seek FDA nod for COVID-19 vaccine
Shareholders to push for detailed COVID-19 pricing strategies from Pfizer, J&J at annual meetings
FDA blasts troubled COVID-19 vaccine producer Emergent for quality control and cleanliness issues
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), Egypt’s Minapharm, the regional leader in recombinant DNA technology, and its Berlin-based subsidiary, ProBioGen AG, announce the agreement to produce
Eli Lilly last month trumpeted topline results showing its rheumatoid arthritis med Olumiant could trigger hair regrowth in the autoimmune disease alopecia areata, where no med
If you gave a pharma a molecule, which one would make the most of it? Eli Lilly, according to IDEA Pharma’s most recent evaluation. It ranks
Lusaka, Zambia & Mumbai, Maharashtra, India: This press release has been reissued because of some updates in the original post, distributed on Wednesday, April 21, 2021 2:44
The next time Biogen reports its quarterly earnings, the world should know whether its controversial Alzheimer’s drug aducanumab sports an FDA approval or whether the
Fresh off of presenting eye-popping data for its obesity drug candidate semaglutide, Novo Nordisk is upping the ante with a more user-friendly version of the treatment. The
In the aftermath of a multi-year cost-cutting spree, generics juggernaut Teva Pharmaceutical Industries has handed its CEO a sizable pay increase. Kåre Schultz’s pay package swelled
Just a few months ago, AbbVie’s Rinvoq was riding high—and racing toward two new indications to boot. But after in-class rival Xeljanz put up some
According to TechSci Research report, “India E Pharmacy Market By Drug Type (Prescription Drugs and Over the Counter (OTC) Drugs) By Product Type (Skin Care,
The 2021 Clinical Researcher of the Year – The Americas will be closing for entry on the 14th of May. Time is running out for
